semaglutide injections india Cheap Ozempic boom meets new concerns over GLP-1 drug risks With semaglutide patents expiring in

Clinical trials show semaglutide produces an average of ~15% body weight loss at 68 weeks, while tirzepatide has demonstrated up to 20.9% weight loss at 72 weeks. Patients in our medical weight loss program which include nutrition and muscle preservation support lose an average of 1520% of their excess body weight on injectable GLP-1 medications, which is clinically meaningful and can improve conditions like type 2 diabetes, high blood pressure, and sleep apnea

May 2002;87 Suppl 2:S193-197

Those with Absorption Issues People with Crohns disease, ulcerative colitis, irritable bowel syndrome (IBS) or other gastrointestinal conditions may struggle to absorb enough nutrients from food or supplements

Typically, both medications are well-tolerated and can lead to profound weight loss, previously achievable only through invasive surgical procedures